Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15148277 | 0.82 | CYP11B1 (0.35) | KDM4EALDH1A1USP2CYP3A4MAPT | |
| SCHEMBL688670 | 0.78 | ALDH1A1 (0.42) | KDM4EALDH1A1USP2CYP3A4MAPT | |
| SCHEMBL29642345 | 0.78 | ALDH1A1 (0.42) | KDM4EALDH1A1USP2CYP3A4MAPT | |
| SCHEMBL30241198 | 0.77 | KDM4E (0.52) | EGFRKDM4EALDH1A1USP2CYP3A4 | |
| SCHEMBL145984 | 0.77 | KDM4E (0.52) | EGFRKDM4EALDH1A1USP2CYP3A4 | |
| SCHEMBL9815925 | 0.76 | TSHR (0.38) | KDM4EALDH1A1USP2CYP3A4MAPT | |
| SCHEMBL718612 | 0.76 | CA3 (0.42) | EGFRFBP1ALDH1A1CYP1A2ESR1 | |
| SCHEMBL16178467 | 0.76 | PTPN1 (0.42) | KDM4EALDH1A1USP2CYP3A4MAPT | |
| SCHEMBL13646423 | 0.76 | KDM4E (0.37) | KDM4EALDH1A1USP2CYP3A4MAPT | |
| Hydrochloric Acid SCHEMBL2482616 | 0.76 | KDM4E (0.50) | EGFRKDM4EALDH1A1USP2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118259012-A | Method for global analysis of functional histidines in proteins | 深圳湾实验室 | 2024-06-28 | — | — | CN | claimed |
| CN-102898315-B | Method for preparing 3-ethynyl-4-fluoroaniline | BIDE PHARMATECH LTD | 2015-01-28 | — | — | CN | claimed |
| CN-102898315-A | Method for preparing 3-ethynyl-4-fluoroaniline | BEPHARM LTD | 2013-01-30 | — | — | CN | claimed |
| US-12595258-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | TOLREMO THERAPEUTICS AG (CH) | 2026-04-07 | — | — | US | disclosed |
| US-12472179-B2 | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer | TOLREMO THERAPEUTICS AG (CH) | 2025-11-18 | — | — | US | disclosed |
| US-20250243191-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| US-20250154140-A1 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF BAX AND/OR BAK, COMPOSITIONS AND USES THEREOF | Sunnybrook Research Institute (CA) | 2025-05-15 | — | — | US | disclosed |
| EP-4479383-A1 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF BAX AND/OR BAK, COMPOSITIONS AND USES THEREOF | Sunnybrook Research Institute (CA) | 2024-12-25 | — | — | EP | disclosed |
| CN-119013259-A | Isoquinoline derivatives as inhibitors of BAX and/or BAK, compositions and uses thereof | 森尼布鲁克研究院 | 2024-11-22 | — | — | CN | disclosed |
| US-20240327394-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2024-10-03 | — | — | US | disclosed |
| CN-118619921-A | Pyrrolidone structure-containing compounds | 正大天晴药业集团股份有限公司 | 2024-09-10 | — | — | CN | disclosed |
| EP-0817775-B1 | QUINAZOLINE DERIVATIVES | PFIZER (US) | 2001-09-12 | — | — | EP | disclosed |
| EP-1110953-A1 | Quinazoline derivatives | PFIZER INC. (US) | 2001-06-27 | — | — | EP | disclosed |
| EP-0831829-A4 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER (US) | 1998-11-25 | — | — | EP | disclosed |
| US-5747498-A | Alkynyl and azido-substituted 4-anilinoquinazolines | PFIZER INC. (US) | 1998-05-05 | — | — | US | disclosed |
| EP-0831829-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0817775-A1 | QUINAZOLINE DERIVATIVES | PFIZER INC. (US) | 1998-01-14 | — | — | EP | disclosed |
| CN-1141298-A | Pyrimidine-fused heterocyclic compound anti-cancer agents | PFIZER (US) | 1997-01-29 | — | — | CN | disclosed |
| WO-1996040142-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996030347-A1 | QUINAZOLINE DERIVATIVES | PFIZER INC. (US) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12472179-B2 | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer | EP300, KRAS, BRD4 | EGFR 577/4885FBP1 2206/4885KDM4E 459/4885 |
| US-12595258-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | SLC10A1, MAPT, SLC6A6 | EGFR 671/4885FBP1 2142/4885KDM4E 3899/4885 |
| US-20240327394-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TP53, MAPT, SLC10A1 | EGFR 1570/4885FBP1 2173/4885KDM4E 2992/4885 |
| US-20250154140-A1 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF BAX AND/OR BAK, COMPOSITIONS AND USES THEREOF | BAK1, BAX, BCL2 | EGFR 3676/4885FBP1 2140/4885KDM4E 3085/4885 |
| US-20250243191-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TP53, MAPT, SLC10A1 | EGFR 1570/4885FBP1 2173/4885KDM4E 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.